SapnaPPatelMD

Melanoma

Inaugural Dr William Robinson Endowed Chair in Cancer Research, Professor of Medicine, Professor of Ophthalmology, Medical Oncologist at the University of Colorado Anschutz Medical Campus

Join to view full profile

Dr. Patel is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Patel's full profile

Already have an account?

Office
13001 E 17th Pl
Aurora, CO 80019
Phone+1 720-848-0305

Education & Training

University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2008 - 2011
University of ColoradoResidency, Internal Medicine, 2005 - 2008
University of Texas Medical Branch School of MedicineClass of 2005

Certifications & Licensure

AZ State Medical License 2023 - 2025
CO State Medical License 2024 - 2025
TX State Medical License 2008 - 2025
WA State Medical License 2023 - 2025
AL State Medical License 2023 - 2024
GA State Medical License 2023 - 2024
LA State Medical License 2023 - 2024
MS State Medical License 2023 - 2024
TN State Medical License 2023 - 2024
American Board of Internal Medicine Medical Oncology
Join now to see all

Clinical Trials

A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands Start of enrollment: 2011 Dec 01
Active, not recruiting
Phase 1
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy Start of enrollment: 2011 Aug 01
Completed
Doxycycline, Temozolomide and Ipilimumab in Melanoma Start of enrollment: 2012 Nov 01
Terminated
Phase 1, Phase 2
HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma Start of enrollment: 2013 May 01
Terminated
Phase 4
Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma Start of enrollment: 2013 Oct 23
Completed
Phase 2
Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists Start of enrollment: 2014 May 01
Completed
Phase 1, Phase 2
LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma Start of enrollment: 2014 Jul 23
Completed
Phase 2
Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery Start of enrollment: 2015 Nov 10
Active, not recruiting
Phase 3
IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma Start of enrollment: 2023 Oct 31
Recruiting
Phase 2, Phase 3
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

218 citations
Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma.
Sapna P Patel, Megan Othus, Yuanbin Chen, G Paul Wright Jr, Kathleen J Yost
The New England Journal of Medicine. 2023-03-02
227 citations
Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade.
Miles C. Andrews, Connie P.M. Duong, Vancheswaran Gopalakrishnan, Valerio Iebba, Wei Shen Chen
Nature Medicine. 2021-07-08
147 citations
Neoadjuvant relatlimab and nivolumab in resectable melanoma.
Rodabe N Amaria, Michael Postow, Elizabeth M Burton, Michael T Tetzlaff, Merrick I Ross
Nature. 2022-11-01

Journal Articles

Author Correction: Neoadjuvant Immune Checkpoint Blockade in High-Risk Resectable Melanoma
Janice N Cormier, Ehab Hanna, Padmanee Sharma, Jennifer A Wargo, Isabella C Glitza, Sapna P Patel, Adi Diab, Jeffrey E Lee, Richard Royal, Randal Weber, Patrick Hwu, J..., Nature
Publisher Correction: Neoadjuvant Immune Checkpoint Blockade in High-Risk Resectable Melanoma
Scott Woodman, Alexander J Lazar, Michael A Davies, Neil Gross, Sapna P Patel, Isabella C Glitza, Ehab Hanna, Stephen Y Lai, Richard Ehlers, Amy Hessel, Padmanee Sharm..., Nature
Neoadjuvant Immune Checkpoint Blockade in High-Risk Resectable Melanoma
Richard Royal, Alexander J Lazar, Adi Diab, Sapna P Patel, Jeffrey E Lee, Padmanee Sharma, Patrick Hwu, Randal Weber, Jeffrey Gershenwald, Carol Lewis, Richard Ehlers,..., Nature

Press Mentions

Melanoma Survivor: Protect Your SkinMarch 19th, 2019
Major Pathologic Response to Neoadjuvant Pembrolizumab in Advanced Melanoma Trial Exceeds 50%October 25th, 2023
Pembrolizumab Trial in Advanced Melanoma Shows Major Pathological Response Exceeding 50%October 25th, 2023